Abstracts Archive - Page 1759 of 2425 - ACR Meeting Abstracts

Abstract Number: 1045 • 2015 ACR/ARHP Annual Meeting
Baricitinib, Methotrexate, or Baricitinib Plus Methotrexate in Patients with Early Rheumatoid Arthritis Who Had Received Limited or No Treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Phase 3 Trial Results
Roy Fleischmann¹, Tsutomu Takeuchi², Douglas E. Schlichting³, William L. Macias³, Terence Rooney³, Sirel Gurbuz³, Ivaylo Stoykov³, Scott D. Beattie³, Wen-Ling Kuo³ and M Schiff⁴, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²Keio University School of Medicine, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Colorado, Denver, CO
Background/Purpose: In 2 completed phase 3 studies, baricitinib (bari) improved disease activity with a satisfactory safety profile in patients (pts) with moderately-to-severely active RA who…
Abstract Number: 1046 • 2015 ACR/ARHP Annual Meeting
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese¹, Joel M. Kremer², Cynthia Kartman³, Douglas E. Schlichting³, Li Xie³, Tara Carmack⁴, William L. Macias³ and Josef S. Smolen⁵, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Durham, NC, ⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib, an oral inhibitor of JAK1/JAK2, improved disease activity with an acceptable safety profile in a phase 3 study (RA-BEACON) of patients with active…
Abstract Number: 1047 • 2015 ACR/ARHP Annual Meeting
Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies
Paul Emery¹, Iain McInnes², Mark C. Genovese³, Josef S. Smolen⁴, Joel Kremer⁵, Maxime Dougados⁶, Douglas E. Schlichting⁷, Terence Rooney⁷, Maher Issa⁷, Stephanie de Bono⁷, William L. Macias⁷, Veronica Rogai⁷, Steven H. Zuckerman⁷ and Peter C. Taylor⁸, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Glasgow Biomedical Research Centre, Glasgow, United Kingdom, ³Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Albany Medical College, Albany, NY, ⁶Paris-Descartes University, Paris, France, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom
Background/Purpose: Baricitinib (bari) is an oral, reversible inhibitor of Janus kinase (JAK)1/JAK2 being developed as QD treatment for patients (pts) with RA. In phase (ph)…
Abstract Number: 1048 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
R Westhovens¹, Rieke Alten², Dace Pavlova³, Favio Enríquez-Sosa⁴, Minodora Mazur⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ²Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³LTD M & M Centrs, Carnikava, Latvia, ⁴CLINSTILE, S.A. DE C.V, Mexico, Mexico, ⁵IMSP Institul de Cardiologie, Chisinau, Moldova, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
Abstract Number: 1049 • 2015 ACR/ARHP Annual Meeting
Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study
Arthur Kavanaugh¹, Lucia Ponce², Regina Cseuz³, Olga Reshetko⁴, Mykola A Stanislavchuk⁵, Maria Greenwald⁶, Annegret Van der Aa⁷, Frédéric Vanhoutte⁷, Chantal Tasset⁷ and Pille Harrison⁷, ¹University of California San Diego, La Jolla, CA, ²Consulta Privada Dra. Lucia Ponce, Temuco, Chile, ³Revita Reumatologiai Rendelo, Budapest, Indonesia, ⁴Regional Clinical Hospital, Saratov, Russia, ⁵Vinnitsa Regional Clinical Hospital n.a. Pirogov, Vinnitsa, Ukraine, ⁶Desert Medical Advances, Palm Desert, CA, ⁷Galapagos NV, Mechelen, Belgium
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
Abstract Number: 1050 • 2015 ACR/ARHP Annual Meeting
Response to Baricitinib at 4 Weeks Predicts Response at 12 and 24 Weeks in Patients with Rheumatoid Arthritis: Results from Two Phase 3 Studies
Joel Kremer¹, Maxime Dougados², Mark C. Genovese³, Paul Emery⁴, Lili Yang⁵, Stephanie de Bono⁵, Thorsten Holzkaemper⁵, Noriko Iikuni⁵, Douglas E. Schlichting⁵ and Josef S. Smolen⁶, ¹The Center for Rheumatology, Center for Rheumatology, Albany Medical College, Albany, NY, ²Service de Rhumatologie B, GHU Cochin, F-75014 France, PARIS, France, ³Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (bari), an oral, reversible inhibitor of Janus kinase (JAK)1/JAK2, improved signs and symptoms in phase 3, placebo (PBO)-controlled studies in patients (pts) with…
Abstract Number: 1051 • 2015 ACR/ARHP Annual Meeting
Serum Calprotectin As Biomarker of Carotid Atherosclerosis in Patients with Primary Sjögren’s Syndrome
Gabriela Moreira Balarini¹, Eliana Zandonade², leandro tanure³, gilda Aparecida ferreira³, Wildner Mardegan Sardenberg⁴, Érica Vieira Serrano⁴, Cléia Coelho Dias⁵, Túlio Pinho Navarro³, João Felipe Tonini⁴, Hilde H Nordal⁶, Piotr Mydel⁷, Johan Gorgas Brun⁸, Karl Albert Brokstad⁹, Eva Gerdts⁸, Roland Jonsson^10,11 and Valeria Valim^4,12, ¹Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., cachoeiro de itapemirim, Brazil, ²Department of Statistic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, ³Department of Locomotor System, Federal University of Minas Gerais, Brazil., belo horizonte, Brazil, ⁴Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vitória, Brazil, ⁵Department of Medical Clinic, Federal University of Espírito Santo (UFES), Brazil., vila velha, Brazil, ⁶Broegelmann Research Laboratory/University of Bergen, Norway, bergen, Norway, ⁷Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ⁸Department of Clinical Science, University of Bergen, Norway, bergen, Norway, ⁹Department of Clinical Science, University of Bergen, Norway., bergen, Norway, ¹⁰Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹¹Broegelmann research laboratory, Bergen, Norway, ¹²Rheumatology, Universidade Federal do Espírito Santo, Vitória, Brazil
Background/Purpose: The relationship between atherosclerosis, traditional risk factors, disease activity and biomarkers is not well explored. We aimed to identify the association of carotid atherosclerosis…
Abstract Number: 1052 • 2015 ACR/ARHP Annual Meeting
Identification of Novel Sjogren’s Syndrome Risk Loci in the Regions of TNFAIP3 and PRDM1
Christopher J. Lessard^1,2, He Li^1,2, John Ice², Indra Adrianto³, Astrid Rasmussen², Kiely Grundahl⁴, Jennifer A. Kelly⁵, Corinne Miceli⁶, Simon Bowman⁷, Susan Lester⁸, Johan G. Brun^9,10, Lasse G. Goransson¹¹, Erna Harboe¹¹, Joel M. Guthridge², Kenneth M. Kaufman^12,13, Per Eriksson¹⁴, Maija-Leena Eloranta¹⁵, Marika Kvarnström¹⁶, Deborah S. Cunninghame-Graham¹⁷, A. Darise Farris², Michael T. Brennan¹⁸, James Chodosh¹⁹, Raj Gopalakrishnan²⁰, Andrew J.W. Huang²¹, Pamela Hughes²², David M. Lewis²³, Lida Radfar²⁴, Michael D. Rohrer²⁵, Donald U. Stone²⁶, Timothy J. Vyse¹⁷, Patrick M. Gaffney², Judith A. James^1,5,27, John B. Harley^12,28, Roald Omdal¹¹, Marie Wahren-Herlenius¹⁶, Gabor G. Illei²⁹, Torsten Witte³⁰, Roland Jonsson^10,31, Maureen Rischmueller^32,33, Lars Rönnblom³⁴, Xavier Mariette³⁵, Juan-Manuel Anaya³⁶, Wan-Fai Ng³⁷, Gunnel Nordmark³⁴, Courtney G. Montgomery², Nelson L. Rhodus³⁸, Barbara M. Segal³⁹, R. Hal Scofield^2,27,40 and Kathy L. Sivils^1,2, ¹Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁵Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, PARIS, France, ⁷Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ⁸Queen Elizabeth Hospital, Adelaide, Australia, ⁹Institute of Internal Medicine, University of Bergen, Bergen, Norway, ¹⁰Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ¹¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹²US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping University, Linköping, Sweden, Linköping, Sweden, ¹⁵Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ¹⁶Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ¹⁸Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹⁹Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ²⁰Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ²¹Department of Ophthalmology and Visual Sciences, Washington University, St Louis, MO, ²²Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ²³College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁴Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ²⁵Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁶Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁷Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²⁸Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁹National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, ³⁰Hannover Medical School, Hanover, Germany, ³¹Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ³²University of Adelaide, Adelaide, Australia, ³³Department of Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ³⁴Rheumatology, Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ³⁵AP-HP, Hopitaux Universitaires Paris-Sud, Université Paris-Sud, Paris, France, ³⁶Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia, ³⁷Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁸Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁹Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ⁴⁰US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a complex autoimmune disease with both environmental and genetic factors playing important roles in its pathophysiology. The goal of this…
Abstract Number: 1053 • 2015 ACR/ARHP Annual Meeting
Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome
Saba Nayar¹, Joana Campos¹, Christopher Buckley¹, Rodger Allen², W.A. Fahy², Andrew Payne² and Francesca Barone¹, ¹University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, ²UCB Pharma, Slough, United Kingdom
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by B cell hyper-activation and exocrine gland infiltration that results in loss of glandular function,…
Abstract Number: 1054 • 2015 ACR/ARHP Annual Meeting
A Potential Role of Type III Interferon in the Glandular Involvement of Sjögren’s Syndrome
Tania Mora¹, Felipe Alonso Masso Rojas², Araceli Paez², Mariana Patlan³, Misael Gómez-Mondragón², Alberto Aranda-Frausto⁴, Maya Chacón Pérez⁵ and Luis M. Amezcua-Guerra^6,7, ¹Rheumatology, National Institute of Cardiology, Mexico City, Mexico, ²Department of Cell Physiology, National Institute of Cardiology, Mexico City, Mexico, ³Department of Immunology, National Institute of Cardiology, Mexico City, Mexico, ⁴Department of Pathology, National Institute of Cardiology, Mexico City, Mexico, ⁵National Institute of Cardiology, Mexico City, Mexico, ⁶Immunology, National Institute of Cardiology, Mexico City, Mexico, ⁷Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico
Background/Purpose: Primary Sjögren's syndrome (pSS) is an autoinmune disorder characterized by lymphocytic infiltration of salivary and lachrymal glands. Recently, it has been showed that plasmacytoid…
Abstract Number: 1055 • 2015 ACR/ARHP Annual Meeting
Expansions of Salivary Gland CD4+ T Cells from Sjögren’s Syndrome Patients: Single-Cell Repertoire Analysis and Correlation with Clinical Measures of Disease
Michelle L. Joachims¹, Kerry M. Leehan^2,3, Christina M. Lawrence³, Astrid Rasmussen³, Lida Radfar⁴, David M. Lewis⁵, Glen D Houston⁶, Kiely Grundahl³, Donald U. Stone^7,8, Kimberly Hefner⁹, R. Hal Scofield^2,10,11, Kathy L. Sivils^2,3, Linda F. Thompson¹² and A. Darise Farris^1,2, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁵College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Heartland Pathology, Oklahoma City, OK, ⁷Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁸King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁹Hefner Eye Care and Optical Center, Oklahoma City, OK, ¹⁰College of Medicine, Section of Endocrinology and Diabetes, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: CD4+ T cells predominate in salivary gland (SG) focal lymphocytic infiltrates in primary Sjögren’s syndrome (pSS). However, their antigen specificity, degree of clonal…
Abstract Number: 1056 • 2015 ACR/ARHP Annual Meeting
Aquaporin Gene Therapy Corrects Bone Morphogenetic Protein 6 Associated Exocrine Gland Dysfunction in Mouse Model of Sjögren’s Syndrome
Hongen Yin¹, Zhennan Lai², Javier Cabrera-Perez³, Patricia Glenton⁴, Ankur Patel⁵, William Swaim⁵, Changyu Zheng⁵, Maria Guimaro⁵, Sandra Afione⁶, Cuong Nguyen⁵, Fred Nyberg⁷ and John A. Chiorini², ¹NIDCR, NIH, Bethesda, MD, ²Mptb, NIH/NIDCR, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Bethesda, MD, ⁴Department of Pathology and Infectious Diseases, University of Florida, Gaineville, FL, ⁵Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁶National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁷Department of Pharmaceutical Bioscience, Division of Biological Research on Drug Dependence, Uppsala University, Uppsala, MD, Sweden
Background/Purpose: Loss of secretory epithelial function is a hallmark of primary Sjögren’s syndrome (pSS). Previously we reported that bone morphogenetic protein 6 (BMP-6) inhibits cell volume…
Abstract Number: 1057 • 2015 ACR/ARHP Annual Meeting
Are Ankylosing Spondylitis, Psoriatic Arthritis and Undifferentiated Spondylarthritis Associated with an Increased Risk of Cardiovascular Disease?
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: It is unclear whether and to what extent different phenotypes of spondylarthritis (SpA) are associated with an increased risk of cardiovascular events such as…
Abstract Number: 1058 • 2015 ACR/ARHP Annual Meeting
Prevalence of Comorbidities in Spondyloarthritis and Evaluation of Their Monitoring: Results of the International Cross-Sectional ASAS-Comospa Study
Anna Moltó¹, Adrien Etcheto¹, Désirée van der Heijde², Robert B. M. Landewé³, Filip van Den Bosch⁴, Maxime Dougados⁵ and on behalf of the ASAS-COMOSPA task force, ¹Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité,, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁴Univ Hosp, Ghent, Belgium, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Increased risk of cardio-vascular disease, and osteoporosis is documented in SpA. Some of these comorbidities (e.g. cardiovascular disease risk) are subject to recommendations, with…
Abstract Number: 1059 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population
Karin Bengtsson¹, Helena Forsblad-d'Elia², Elisabeth Lie¹, Eva Klingberg¹, Mats Dehlin¹, Sofia Exarchou³, Ulf Lindström¹, Johan Askling⁴ and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Departments of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: There is a known association between conduction disturbances and ankylosing spondylitis (AS). The risk of conduction disturbances in other phenotypes of spondylarthritis (SpA) is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].